AbbVie Inc (ABBV)vsAbcellera Biologics Inc (ABCL)
ABBV
AbbVie Inc
$234.89
+0.06%
HEALTHCARE · Cap: $391.50B
ABCL
Abcellera Biologics Inc
$5.74
-11.77%
HEALTHCARE · Cap: $1.60B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 79209% more annual revenue ($62.82B vs $79.21M). ABBV leads profitability with a 5.8% profit margin vs -181.7%. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
ABCL
Hold41
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-48.1%
Fair Value
$146.22
Current Price
$234.89
$88.67 premium
Margin of Safety
+64.7%
Fair Value
$8.86
Current Price
$5.74
$3.12 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 32.2%
Conservative balance sheet, low leverage
Growing faster than its price suggests
Generating 3.6B in free cash flow
Revenue surging 96.3% year-over-year
Conservative balance sheet, low leverage
Reasonable price relative to book value
Earnings expanding 45.9% YoY
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 46.2%
Distress zone — elevated risk
Distress zone — elevated risk
Smaller company, higher risk/reward
ROE of -15.3% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.61 suggests the stock is reasonably priced for its growth.
Bull Case : ABCL
The strongest argument for ABCL centers on Revenue Growth, Debt/Equity, Price/Book. Revenue growth of 96.3% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 108.6x leaves little room for execution misses.
Bear Case : ABCL
The primary concerns for ABCL are Altman Z-Score, Market Cap, Return on Equity.
Key Dynamics to Monitor
ABBV profiles as a value stock while ABCL is a hypergrowth play — different risk/reward profiles.
ABCL carries more volatility with a beta of 1.20 — expect wider price swings.
ABCL is growing revenue faster at 96.3% — sustainability is the question.
ABBV generates stronger free cash flow (3.6B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 41/100) and 12.4% revenue growth. ABCL offers better value entry with a 64.7% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Abcellera Biologics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
AbCellera Biologics Inc. develops an antibody discovery platform. The company is headquartered in Vancouver, Canada.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?